Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes by Manchanda, R et al.
1 
 
Randomised trial of population based BRCA testing in Ashkenazi Jews: Long term 
outcomes 
 
*Ranjit Manchanda1,2,3, Matthew Burnell3, Faiza Gaba1, Rakshit Desai3, **Jane Wardle4, Sue 
Gessler 3, Lucy Side5, Saskia Sanderson4, Kelly Loggenberg6, Angela F Brady7, Huw Dorkins8, 
Yvonne Wallis9, Cyril Chapman10, Chris Jacobs11, 12, Rosa Legood13, Uziel Beller14, Ian 
Tomlinson15, Usha Menon3, and Ian Jacobs16. 
1Barts Cancer Institute, Queen Mary University of London, Old Anatomy Building, 
Charterhouse Square, London, EC1M 6BQ, UK  
2Department of Gynaecological Oncology, St Bartholomew’s Hospital, London, UK, EC1A 7BE 
3MRC Clinical Trials Unit, University College London, 90 High Holborn, London, UK WC1V 6LJ 
4Behavioral Sciences Unit, Dept Epidemiology and Public Health, University College London 
5University Hospital Southampton NHS Foundation Trust 
6Dept Clinical Genetics, North East Thames Regional Genetics Unit, Great Ormond Street 
Hospital, London, UK 
7North West Thames Regional Genetics Service, Northwick Park Hospital, Harrow, HA1 3UJ, 
UK  
8St Peter's College, University of Oxford, Oxford, UK 
9West Midlands Regional Genetics Laboratory, Birmingham Women's NHS Foundation Trust, 
Birmingham, UK  
10Dept Clinical Genetics, West Midlands Regional Genetics Service, Birmingham Women's 
NHS Foundation Trust, Birmingham, UK   
11Dept Clinical Genetics, Guy’s Hospital, London SE1 9RT, UK  
12University of Technology Sydney, Australia, NSW 2007 
2 
 
13Department of Health Services Research and Policy, London School of Hygiene & Tropical 
Medicine, London WC1H 9SH, UK 
14Department of Gynaecology, Shaare Zedek Medical Center, Jerusalem, Israel 
15Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK 
16University of New South Wales, Australia, Level 1, Chancellery Building, UNSW Sydney 
NSW 2052  
 
*Corresponding Author:  
Dr Ranjit Manchanda 
Consultant Gynaecological Oncologist, Clinical Senior Lecturer 
Barts Cancer Institute, Centre for Experimental Cancer Medicine  
Charterhouse Square, London EC1M 6BQ  
Department of Gynaecological Oncology 
Bartshealth NHS Trust, Royal London Hospital 
10th Floor, South Block, Whitechapel Road, London E1 1BB,  
Email- r.manchanda@qmul.ac.uk  
Running Title 
Population based BRCA testing in Ashkenazi Jews 
Word count: 3464 
**Deceased 
 
  
3 
 
ABSTRACT 
Objective 
Unselected population-based BRCA-testing provides the opportunity to apply genomics on a 
population-scale to maximise primary prevention for breast-&-ovarian cancer. We compare 
long-term outcomes of population-based and Family-History (FH)/Clinical-criteria based 
BRCA-testing on psychological-health and quality-of-life. 
Design 
Randomised-Controlled-Trial (RCT) (ISRCTN73338115) GCaPPS, with two-arms: 
(a)Population-Screening (PS); (b)FH/Clinical-criteria based testing. 
Setting 
North-London Ashkenazi-Jewish (AJ) population 
Population/Sample: AJ women/men 
Methods:   
Population-based RCT (1:1). Participants were recruited through self-referral, following pre-
test genetic-counselling from North-London AJ population.  
Inclusion criteria: AJ-women/men >18-years. Exclusion-criteria: prior BRCA-testing or first-
degree-relatives of BRCA-carriers.  
Interventions: Genetic-testing for three Jewish BRCA founder-mutations:  
185delAG(c.68_69delAG), 5382insC(c.5266dupC) and 6174delT(c.5946delT), for (a) all 
participants in PS-arm; (b) those fulfilling FH/clinical-criteria in FH-arm. Linear-mixed models 
and appropriate contrast-tests were used to analyse impact of BRCA-testing on 
psychological and quality-of-life outcomes over 3-years. 
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Main Outcome Measures: Validated questionnaires (HADS/MICRA/HAI/SF12) used to 
analyse psychological well-being/quality-of-life outcomes at baseline/1-year/2-years/3-
years follow-up. 
Results:  
1034 (women=691/men=343) participants randomized to PS(n=530) or FH(n=504) arms. 
There was a statistically significant decrease in anxiety(p=0.046) and total anxiety-&-
depression scores(p=0.0.012) in the PS-arm compared to FH-arm over 3-years. No significant 
difference was observed between FH/PS-arms for depression, health-anxiety, distress, 
uncertainty, quality-of-life or experience-scores associated with BRCA-testing. Contrast-tests 
showed a decrease in anxiety (p=0.018), health-anxiety (p<0.0005), and quality-of-life 
(p=0.004) scores in both PS and FH groups over time. 18/30(60%) BRCA-carriers identified 
did not fulfil clinical-criteria for BRCA-testing. The total BRCA-prevalence= 
2.9%(CI:1.97%,4.12%). BRCA1-prevalence=1.55%(CI:0.89%,2.5%); BRCA2-
prevalence=1.35%(CI:0.74%,2.26%). 
Conclusion:  
Population-based AJ BRCA-testing doesn’t adversely affect long-term psychological well-
being or quality-of-life, decreases anxiety and could identify up-to 150% additional BRCA-
carriers. 
Trial-registry:  
ISRCTN-73338115  
Funding:  
Eve-Appeal-Charity (Grant-GTCV) 
Key Words:  
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BRCA1, BRCA2, genetic testing, population testing, Ashkenazi Jews, psychological, quality of 
life 
Tweetable Abstract:  
Population BRCA testing in Ashkenazi Jews reduces anxiety & doesn’t adversely affect 
psychological health or quality-of-life. 
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INTRODUCTION 
Traditionally ovarian cancer (OC) and breast cancer (BC) prevention has been targeted at 
high-risk individuals like BRCA1/BRCA2-carriers. BRCA1/BRCA2-carriers have a 17-44% OC-
risk and 69-72% BC-risk till age 80-years.1 Carrier identification offers the opportunity of 
screening/prevention to reduce the burden of BC/OC in women. At-risk BRCA-mutation 
carriers can opt for a range of options to minimise risk: risk-reducing salpingo-
oophorectomy (RRSO) to reduce their OC-risk;2, 3 MRI/mammography screening, risk-
reducing mastectomy (RRM)4, or chemoprevention with selective estrogen-receptor 
modulators (SERM) to reduce their BC-risk;5 as well as pre-implantation genetic diagnosis 
(PGD).6 The current practice of clinical-criteria/family-history (FH) based BRCA-testing is only 
moderately effective at identifying mutations and has poor ability to rule out the absence of 
one.7 Inadequate public and health-professional awareness, complexity of the current 
structure/referral-pathways, limited genetic-counselling services, has led to restricted 
access and under-utilisation of genetic-testing services.8-10 Population-testing overcomes 
the limitations of the current FH/criteria-based testing enabling the identification of many 
more at-risk BRCA-carriers.  
Population-based BRCA-testing has been investigated in the Ashkenazi-Jewish (AJ) 
population. It was found to be feasible, acceptable,11 cost-effective, with high satisfaction, 
and deliverable in a community setting using non-inferior, cost-efficient pre-test counselling 
approaches.12-15 Israeli and Canadian population-cohort studies show increased anxiety/distress in 
mutation carriers at 6-months/1-year.16, 17 These studies provided only post-test counselling. 
However, overall satisfaction rates were high and similar for carriers and non-carriers (>91%).16 
Short-term increase along-with long-term decrease in distress and uncertainty has also been 
reported following BRCA-testing in high-risk women.16, 18-21 Some studies also found 
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increase and no change in anxiety or depression over 1-year in high-risk women.20 The 
Genetic-Cancer-Prediction through Population-Screening (GCaPPS) study is the only 
randomized-controlled-trial ( RCT) directly comparing BRCA-testing using FH-based clinical-
criteria with Population-Screening (PS) or BRCA-testing all-participants irrespective of FH 
(ISRCTN:73338115). Short-term (3-month) outcomes demonstrated that population-testing 
(compared to FH-testing) did not adversely affect psychological well-being or quality-of-life, 
while overall anxiety and uncertainty decreased at 3-months follow-up.14 However, psycho-
social outcomes of BRCA-testing may change with time and long-term consequences can 
differ from short-term outcomes. RCT data of long-term psychological-health and quality-of-
life outcomes of ‘population-based’ BRCA-testing have not previously been reported. In this 
paper we report on 3-year psychosocial/quality-of-life outcomes from the GCaPPS trial. 
 
METHODS 
Design: 
RCT (ISRCTN73338115), with participants randomly allocated to one of two-arms: 
population-screening (PS) arm, and family-history (FH)-arm. Inclusion-criteria: age >18-years 
and AJ-ethnicity. Exclusion-criteria: known BRCA-mutation, first-degree-relative (FDR) of a 
BRCA-carrier or previous BRCA-testing. Recruitment was undertaken via self-referral 
through the North-London Jewish community. Study leaflets were made available through 
community charities, religious-groups, a local pharmacy chain (Boots) and study web-site. 
All participants received structured non-directive pre-test genetic-counselling prior to 
consenting for BRCA-testing. Baseline data were collected at initial appointment. Consenting 
participants were randomized (1:1) post-counselling using a computer generated random-
number algorithm. Genetic-counsellors were blinded to group allotment during counselling 
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and recruitment. Participants were notified of their group allocated by post. Randomisation 
was undertaken three weeks after consent to provide a window period for early withdrawal 
prior to genetic-testing in case volunteers changed their mind. These details have been 
described earlier.14 
 
BRCA-testing for the three AJ founder-mutations (185delAG(c.68_69delAG), 
5382insC(c.5266dupC) and 6174delT(c.5946delT)) was performed in a NHS clinical-genetics 
laboratory on all PS-arm volunteers and only FH-arm volunteers fulfilling standard FH-based 
criteria. These clinical/FH-criteria have been described earlier and are given in Table-S1.14  
BRCA-mutation positive (and equivalent number of randomly selected BRCA-mutation 
negative) individuals received their result at standard face-to-face post-test counselling. 
BRCA-carriers were referred to a NHS regional genetics-clinic for further management. Most 
BRCA-mutation negative volunteers obtained test results by mail. BRCA founder-mutation 
negative participants who had strong family-histories of cancer fulfilling standard non-AJ 
high-risk criteria were also advised referral to genetic-clinics. 
 
GCaPPS Phase-1 was powered to assess psychological outcomes. A sample size of 509/arm 
had 90% power to detect a difference of 1.2 points in total HADS scores between the two 
groups assuming a common SD of 5.9 and α=0.05. We report on long-term (up-to 3-years) 
outcomes on (a)psychological-health, (b)quality-of-life and (c)mutation rate. Customised 
questionnaires were used to collect socio-demographic and FH data. Validated 
questionnaires were used to assess psychological and quality-of-life outcomes. Anxiety-&-
Depression: Hospital Anxiety-&-Depression Scale (HADS);22 Quality-of-Life: SF12-
questionnaire (Physical-Health Component-scale (PCS) and Mental-Health Component-scale 
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(MCS));23 Health-Anxiety: very-short Health-Anxiety Inventory (HAI),24 ; Impact of genetic-
test result disclosure: Multidimensional-Impact of Cancer-Risk-Assessment (MICRA) 
questionnaire (distress, uncertainty, and positive-experience scales).25 Data were collected 
at baseline (pre-counselling) and annually for 3-years post-result. FH-negative FH-arm 
participants were offered BRCA-testing at the end of the study after 3-years follow-up. 
 
Statistical analysis: 
Descriptive statistics were used for baseline characteristics. The primary comparison of 
outcomes involves an intention-to-treat analysis between the PS and FH arms. As outcome 
data are collected over multiple time-points, we modelled the results using random-effects 
for HADS (including subscales ‘anxiety’ and ‘depression’), MICRA (including subscales 
‘distress’, ‘uncertainty’ and ‘positive-experience’), SF12 (including subscales ‘physical’ and 
‘mental’) and HAI. Each scale/subscale was analysed assuming the outcome as a continuous 
response variable. The responses to the scales at the time-points ‘baseline’, 1-year, 2-years 
and 3-years were analysed using linear-mixed models, where a random-intercept term 
represented the unexplained heterogeneity corresponding to each subject. Each time-point 
was included as a fixed-effect and interacted with the group-term (‘family-history’ or 
‘population-screening’) resulting in all 8 group by time mean values being freely estimable, 
and reflecting individual group differences over time. In addition, the model was adjusted 
for gender (men versus women), marital status (married/cohabiting versus 
widowed/divorced/single), income (<£10,000, £10,000-to-<£20,000, £20,000-to-<£30,000, 
£30,000-to-<£40,000, £40,000-to-<£50,000 and >£50,000), education (degree-level/above 
versus no formal qualification/GCSE/O-level/CSE/NVQ1/NVQ2/A-level education), family-
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history (low-risk versus high-risk) and age. The group-by-time interaction reflects potential 
differences over time between groups. 
 
Post-modelling, we considered 2 specific pre-defined contrast tests (each on 3-degrees of 
freedom). Firstly, we assessed a time-effect for each group (specifically whether the mean 
value at time-points 1, 2 and 3 years were jointly different from the baseline level), and 
secondly, we assessed group differences adjusted for any baseline difference (whether the 
mean group differences value at time-points 1, 2 and 3 years were jointly different from the 
baseline group difference). This latter test was to establish whether the effect of PS could be 
deemed as detrimental compared to the FH modality by any outcome measure. Potential 
group differences over the 4 time-points were also explored visually, to help interpret the 
model parameters for group when interacted with time. Stata’s margin command was used 
to make mean predictions over the sample for each of the 8 group-by-time interactions. 
These marginal predictions, and their confidence-intervals, were then plotted. Statistical-
analyses used Stata-11.0 (Stata-Corp LP, Texas/USA).  Two-sided p-values are reported for 
all statistical tests. 
Funding:  The study underwent peer-review and was funded by The Eve-Appeal Charity 
(Grant award- GTCV). The funding body (Eve-Appeal) had no role in the study design, data 
collection, analysis, interpretation or writing of the report or decision to submit for 
publication. The research team was independent of funders.  
Core Outcome Sets (COS): There are no Core Outcome Sets for population or BRCA-testing 
at present. 
Patient & Public Involvement (PPI): 
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During the development of the GCaPPS study a wide-ranging process of engagement was 
undertaken with all sections of the Jewish community.11 This lasted a year. This included 
representatives from the Orthodox, Liberal, Reform, Masorti as well as the Unaffiliated 
sections of the community. It included a number of religious leaders, Rabbis and 
representatives, Jewish Charities, the Beth Din and stakeholders from the medical 
community. Also involved were cancer charities and patient support groups. This exercise 
enabled exchange of ideas and understanding of underlying concerns or issues resulting 
from BRCA testing and conduct of the research. It provided community inputs into study 
protocol development, communication strategy, development of participant/patient facing 
materials, study conduct/delivery and representation on governance committees. It 
generated support and awareness for the study. Delivery and completion of the study would 
not have been possible without it. 
 
RESULTS: 
1168 volunteers underwent pre-test counselling, of whom 1042(89%) consented to BRCA-
testing over a two year recruitment period. Eight elected to withdraw from the study within 
the three weeks window period. 1034 (691 women, 343 men) were randomized to the 
PS(n=530) or FH(n=504) arms. The consort flow-chart is given in Figure-1. A further 17 
participants (PS=10,FH=7) withdrew during the follow-up period. Reasons provided 
included: death of spouse(n=1), death(n=2), relocation(n=1), changed mind(n=4), not 
wanting to fill questionnaires(n=4), no longer relevant(n=2), none(n=3). The PS and FH arms 
were comparable at baseline in terms of age, gender, marital-status, children, income, 
education, Jewish affiliation and family-history of cancer. These baseline characteristics 
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have been described earlier and are given in Table-S2.14 The questionnaire response rate 
was 99% at baseline, 77-80% at 1-year, 71-72% at 2-year, 64-71% at 3-year (Figure-1). 
 
Values for all outcome-scales (anxiety, depression, health-anxiety, physical/mental quality-
of-life, distress, uncertainty and positive-experience) by group over time are given in Table-
1. Contrast-tests to assess the joint-effect of difference in these outcomes between FH and 
PS groups over time (Table-2) showed a statistically significant decrease in anxiety(p=0.046) 
and overall HADS(p=0.0.012) scores in the PS-arm compared to FH-arm over 3-years time 
(Table-2,Figure-2). There was no statistically significant difference in depression-scores 
between PS and FH groups over time (Table-2,Figure-2). Overall, anxiety within both 
PS(p<0.0005) and FH(p=0.018) groups decreased over time, while the total HADS-scores 
decreased over time in PS-arm alone (p<0.0005) (Tables-1,2;Figure-2).  There was a small 
increase in depression scores over time within the FH-testing group (p=0.035) but not within 
PS-group (Table-1,2). There was no statistically significant difference in overall quality-of-life 
or physical/mental quality-of-life scores between the PS and FH arms over time (Table-
2,Figure-S1). However, there was a small significant decrease in overall quality-of-life scores 
seen in both the FH(p=0.005) and PS(p=0.004) groups over three years (Table-2). Though 
statistically significant the absolute decrease is extremely small (change in score from ~101 
to 100), not clinically meaningful and consistent with decreasing physical quality-of-life seen 
with increasing age in population level data. BRCA-testing was associated with an overall 
decrease in health-anxiety within both groups over time (p<0.0005), however, no significant 
difference in health-anxiety was observed between FH and PS based testing over time 
(Tables-1&2;Figure-2). There was no statistically significant long-term difference in distress, 
uncertainty or positive-experience scores between FH and PS approaches to BRCA-testing 
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(Table-2, Figure-S2).  Contrast-tests did not show a decrease/change in distress or 
uncertainty associated with BRCA-testing within the groups over long-term follow-up (Table-
2, Figure-S2). Both groups showed a similar increase in positive-experience scores over 
time(p<0.005) (Table-2). These results indicate that there is no evidence that population-
based BRCA-testing has any detrimental/adverse psychological or quality-of-life effects 
compared to a FH-based approach over the long-term. There is some evidence of potential 
benefit with lower long-term anxiety and HADS scores with population-based BRCA-testing 
compared to FH-based testing. 
 
Linear-mixed models outputs showing the association of covariates with the different 
outcomes are given in Table-S3. Higher income was significantly associated with lower levels 
of anxiety(p<0.0005), depression(p<0.005), health-anxiety(p=0.02), distress(p<0.005), 
uncertainty (p=0.003) and higher quality-of-life scores(p<0.005) with genetic-testing (Table-
S3). Overall men (compared to women) had lower levels of anxiety(p<0.0005), health-
anxiety(p=0.001) and higher quality-of-life(p<0.005) and positive-experience(p<0.005) 
scores. Higher education was associated with lower mental quality-of-life(p=0.004) scores 
and lower levels of post-testing distress (p=0.006) and uncertainty(p=0.007) (Table-S3). A 
strong FH of cancer (FH-positive) was associated with higher depression-scores(p=0.025) but 
not with any other outcome variables (Table-S3). Increasing age was associated with 
increased depression-scores(p=0.01) but lower anxiety levels(p<0.005), lower positive-
experience scores(p<0.005) and lower physical quality-of-life(p<0.0005) but higher mental 
quality-of-life scores(p<0.0005) (Table-S3). 
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530 participants in the PS-arm and 66 in the FH-arm underwent BRCA-testing. Thirteen 
(BRCA1:7,BRCA2:6) carriers were detected in the PS-arm, of whom 3 were FH-positive. Nine 
carriers (5 BRCA1, 4 BRCA2) were detected in the FH-arm.14 Following completion of the 
study 3-year follow-up, all FH-negative volunteers in the FH-arm were offered BRCA-testing. 
At the time of our last report,14 228 FH-negative volunteers in the FH-arm had not 
completed BRCA-testing. We identified 3 additional BRCA-carriers in them. Thus 438 FH-
negative volunteers in the FH-arm underwent BRCA-testing after completing their 3-year 
follow up making it a total of 8 BRCA-carriers in the FH-negative FH-arm sub-group. Hence, 
the total BRCA-prevalence in the cohort is 30/1034 (2.9% CI:1.97%,4.12%). Of these 18(60%) 
did not fulfil clinical-criteria for BRCA-testing and would not have been detected by FH 
alone. The overall prevalence for BRCA1 was 1.55%(CI:0.89%,2.5%) and for BRCA2 was 
1.35%(CI:0.74%,2.26%). The combined BRCA-prevalence in FH-positive individuals from both 
arms is 9.4% (CI:4.9%,15.8%) and prevalence in FH-negative individuals is 1.99% 
(CI:1.2%,3.1%). 
DISCUSSION 
Main Findings: 
To the best of our knowledge GCaPPS remains the only RCT comparing unselected 
population-based and FH/Clinical-criteria driven approaches to BRCA-testing.  We found no 
statistically significant long-term difference in levels of depression, health-anxiety, distress, 
uncertainty, and overall quality-of-life when directly comparing population-based and 
FH/Clinical-criteria based approaches to BRCA-testing in Ashkenazi-Jews.  Of the decrease in 
anxiety, uncertainty and distress with BRCA-testing seen initially on short-term follow-up,14 
only a decrease in anxiety was maintained over the long-term. Additionally, population-
based BRCA-testing had the advantage/benefit of being associated with a significantly 
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greater reduction in long-term anxiety and overall anxiety-&-depression (HADS) scores 
compared to FH-based BRCA-testing. While this decrease was statistically significant, the 
effect-size is small (Table-1) and probably unlikely to be clinically meaningful. Nevertheless, 
the overall long-term decrease in anxiety and health-anxiety associated with population-
based BRCA-testing is reassuring and consistent with earlier findings reporting psychological 
benefits associated with BRCA-testing in high-risk women.26-28 However, no change in short-
term anxiety was reported in the Israeli population-cohort study over 6-months follow-up.16 
 
Strengths and Weaknesses: 
The strengths of our study include the randomised design, pre-test counselling, use of 
validated questionnaires, involving both men and women, long-term follow-up, and good 
questionnaire response rates. Weaknesses include the lack of qualitative-data. However, 
qualitative-data from an Israeli study29 is supportive of population-testing and complements 
the quantitative findings from our and other studies. Findings from our study are limited to 
the Jewish-population. Levels of income and education in the Jewish-population (and our 
study participants) are higher than the wider UK general-population. Socio-cultural 
differences exist between the Jewish and non-Jewish populations. Study outcomes with 
respect to impact on psychological-health and quality-of-life therefore cannot be directly 
extrapolated to the non-Jewish general-population and generalizability beyond the Jewish-
population is limited. Applicability of such an approach to the general non-AJ population 
requires more research. 
Interpretation 
Our results are reassuring as they reconfirm that the lack of adverse short-term 
consequences to psychological-health and quality-of-life from population-testing seen at 3-
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months14 are maintained over the long-term. Although, we did not find a difference in 
cancer related distress or uncertainty between FH and PS testing approaches, increased 
levels of distress have been reported in mutation-carriers in two population-cohort studies 
at up-to 1-year post-test results.16, 17 However, these studies lacked a current practice 
comparator control-arm and their findings are similar to outcomes from testing high-risk 
women.18, 20 The increase in positive-experience scores seen at short-term follow-up14 
persisted over the long-term. This could reflect reducing family support or relief with the 
passage of time following receipt of test result. The small decrease in quality-of-life scores 
found with time are consistent with normative data showing decrease in quality-of-life with 
age30, 31 and the lack of difference observed between the two BRCA-testing approaches is 
reassuring. The baseline distribution of anxiety, depression32 and quality-of-life31, 33 scores in 
our cohort are similar to normative UK-population data.34 Having a strong FH of cancer was 
associated with higher depression-scores across the cohort but not any outcome measures 
assessed. Both increased distress35 and no adverse psychological consequences36 have been 
reported earlier in high-risk Jewish women following genetic-testing.  
 
There are several differences between GCaPPS and the two single-arm Israeli and Canadian 
population studies including a randomised design, provision of pre-test counselling prior to 
BRCA-testing (in addition to post-test counselling) and inclusion of both women and men in 
our study. 20% of Canadian participants (and 50% BRCA-carriers) who received only post-
test counselling following population-based BRCA-testing expressed a preference for pre-
test counselling after receiving their results.17 Nevertheless, high satisfaction levels (91-93%) 
have been reported with population-based BRCA-testing in the Canadian and Israeli studies 
on quantitative16, 17 and qualitative analysis.29 Pre-test genetic-counselling undertaken in 
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our study offered the opportunity to explore complexities and limitations around risk 
estimation incorporating an individual’s family-history and demographic variables as well as 
address any specific issues related to BRCA-testing prior to undergoing genetic-testing.11 
This affected decision making11 and remains part of current standard clinical guidelines prior 
to genetic-testing.37 The Israeli and Canadian studies successfully implemented a model of 
large scale BRCA-testing without pre-test counselling. An ongoing US study is also using that 
approach with a web-based consent process.38 A pilot UK-study has shown 
feasibility/acceptability of a web-based decision-aid plus telephone helpline for consent and 
recruitment to population-based genetic-testing.39 There are currently no randomised-trial 
data comparing population-based BRCA-testing with and without pre-test counselling. As 
access to testing broadens on a population basis the newer more time/cost-efficient 
approaches to consenting for genetic-testing will need robust evaluation (in randomised 
trials) to establish effectiveness and non-inferiority/equivalence to the more established 
standard counselling approaches. 
 
The slightly higher income and education levels seen in our study participants is consistent 
with the income/education levels found in the UK Jewish-population compared to the 
general-population. The significant associations of some study outcome variables seen with 
demographic variables of income, gender, age and education are largely consistent with 
observations from population-based data reported in other population-cohorts. Importantly 
a number of these findings could relate to the large sample size and in view of the small 
effect-sizes, are unlikely to be clinically important.  
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The overall 2.9% BRCA-prevalence is marginally higher but well within confidence-intervals 
of other reports.40-42 Our finding of high BRCA-prevalence in FH-negative individuals and 
60% BRCA-carriers lacking clinical-criteria for testing is similar to other studies which 
reported this to range from 40-63%.40-42 Potential reasons for absence of FH include, small 
family-size, paternal transmission, male preponderance, few women inheriting the 
mutation, poor communication, and chance. Our data coupled with other reports clearly 
illustrate the limitations of a clinical-threshold/criteria-based approach over unselected 
population-based BRCA-testing.  
 
Most of our healthcare structure and ongoing research is predominantly aimed towards 
disease diagnosis/treatment rather than illness prevention. There is a huge opportunity for 
the health-system to utilise advances in technology and bioinformatics to maximise 
identification of mutation-carriers/high-risk individuals who can benefit from consequent 
cancer screening and prevention. The traditional approach to BRCA-testing uses an apriori 
FH-based probability-threshold and misses many BRCA-carriers. Individuals in the family 
need to develop cancer before unaffected relatives can be identified. It requires awareness 
of FH and its importance by family members and the GP/health-professional. This gate-
keeper approach restricts access, delays identification of unaffected individuals and is 
associated with under-utilisation of genetic-testing.8, 10 We found only 3% of general and 
11% AJ BRCA-carriers have been identified in a 16-million population across Greater-
London.9 It is likely a similar picture exists across most parts of the Western hemisphere. 
The current system is failing to achieve the maximum/full potential for genetic cancer 
prevention, and highlights the need to explore other strategies. 
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Next-generation-sequencing technologies43, 44, falling costs and advances in computational 
bioinformatics makes population-testing feasible. The rapidly changing genomic landscape, 
improved genetic understanding of disease and increasing awareness offers a massive 
opportunity to apply this knowledge and technology on a broad population scale to make an 
important shift in healthcare towards disease prevention. GLOBOCAN data suggest OC/BC 
cases will increase by 24%/27% in the UK and by 55%/55% worldwide over the next 20-
years.45 Poor OC-survival rates and effective options available for BC and OC prevention in 
high-risk women highlight the acute need for using population genomics to maximise cancer 
prevention. Our data12-15, 46 coupled with other reports from the literature16, 17, 29, 40, 42 
strongly support a change in paradigm and implementation of population-based BRCA-
testing in the Jewish-population. This will need to be accompanied by context specific 
expansion in genetics and downstream management infrastructure along-with development 
of logistics and implementation pathways in a planned and organised manner. While recent 
data suggest genetic testing for BC/OC gene mutations could be cost-effective in general-
population women too,47 additional research including general-population implementation 
studies are needed to address knowledge gaps before that step can be considered.  
 
Chronic disease is a major public health burden. CDC reports the top five causes of deaths 
as: 1)heart-disease 2)cancer 3)lung-disease 4)accidents 5)strokes.48 50% adults have ≥1 and 
25% adults have ≥2 chronic-health conditions and the latter accounts for >90% Medicare 
expenditure. In England chronic-conditions account for 50% GP appointments, 64% 
outpatient-appointments, 70% inpatient-bed days, and 70% of the total health-care spend.49  
The increasing prevalence of long-term/chronic conditions (including cancer) is the biggest 
challenge facing the health-system.49 A population-testing approach provides opportunity 
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for exploring strategic change by nudging the needle of health-care towards prevention. 
Population-based BRCA-testing in the Jewish-population provides the first model to explore 
population-genomics for preventing chronic-disease.  
Conclusion: 
Population-based BRCA-testing in the Jewish-population doesn’t adversely affect long-term 
psychological well-being or quality-of-life and is associated with decreased anxiety 
compared to FH/criteria-based testing. It identifies many more BRCA-carriers, is acceptable, 
feasible, safe and even cost-saving. It provides the first implementable model for the 
application of population-genomics for cancer prevention. We call for a change in guidelines 
to reflect this.  
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